Table S1. List of primers used in this study

	Forward	Reverse
q-PCR		
Nucleolin	5’-ACTGACCGGGAAACTGGGTC-3’	5’-TGGCCCAGTCCAAGGTAACT-3’
GAPDH	5’-GATTCCACCCATGGCAAATTC-3’	5’- AGCATCGCCCCACTTGATT-3’
E2F2	5’-ACAAGGCCAACAAGAGGCTG-3	5’-TCAGTCCTGTCGGGCACTTC-3’
c-myc	5’-CAGTGGGCTGTGAGGAGGTT-3’	5’-CAGGCTCCTGGCAAAAGGT-3’
miR-185-3p	5’-ACACTCCAGCTGGGTGGAGAGAAAGGCAGT-3’	5’-ACTGACTGATGCAATCTCAACTGGTGTCGTGGA-3’
ChIP-PCR		
5s rDNA	5’-ACGGCCATACCACCCTGAA-3’	5’-GCCAAAGAAAAAGCCTACAGCA-3’
miR-185	5’-CCCCTCCAGGCTCACCTT-3’	5’-TGTGTGCTCTGCAGCTGTGAT-3’
miR-185 ct	5’-TGAGCCTCACGACGCACAT-3’	5’-TGGAGCACATAGGGACTTGGT-3’
Constructs		
pGL3-miR-185	5’-CGGGGTACCACTTATACTACCCAGTCATTAAGAC-3’	5’-CCGCTCGAGACAGCCCAGAAGCATCTGAACATCT-3’
pGL-miR-185 CT	5’-CGGGGTACCGCACTTGCTGACATTTGGGGGTACA-3’	5’-CCGCTCGAGAGGGCAAGAACCCAAGAGTCACTTG-3’
pSIF-miR-185-3p	5’-GATCCGATTGGAGAGAAAGGCAGTTCCTGATGGTCCCCTCCCCAGGGGCTGGCTTTCCTCTGGTCTTTTTG-3’	5’-AATTCAAAAAGACCAGAGGAAAGCCAGCCCCTGGGGAGGGGACCATCAGGAACTGCCTTTCTCTCCAATCG-3’
pSIF-miR-185-3pΔ	5’-GATCCGATTGGAGAGAAAGCGTCTTCCTGATGGTCCCCTCCCCAGGCCGAGGCTTTCCTCTGGTCTTTTTG3’	5’-AATTCAAAAAGACCAGAGGAAAGCCTCGGCCTGGGGAGGGGACCATCAGGAAGACGCTTTCTCTCCAATCG-3’
pMIR-c-Myc	5’-CTAGTCTGCAGAGACAGATCAGCAACAACCGAAAATGCACCAGCCCCAGGTCCTCGGACACCGAGA-3’	5’-AGCTTCTCGGTGTCCGAGGACCTGGGGCTGGTGCATTTTCGGTTGTTGCTGATCTGTCTATGCAGA-3’
pMIR-c-MycΔ	5’-CTAGTCTGCAGAGACAGATCAGCAACATGGGATAATGCAGGTCGGGGAGGTCCTCGGACACCGAGA-3’	5’-AGCTTCTCGGTGTCCGAGGACCTCCCCGACCTGCATTATCCCATGTTGCTGATCTGTCTATGCAGA-3’

Figure S1. miRNA array expression data from RNA samples 1 and 2. Red denotes high expression and green denotes low expression relative to the median. Only the representative miRNA nodes that were significantly changed between samples 1 and 2 as indicated in Fig. 1A are shown here.

Figure S2. Exogenous and endogenous c-Myc binds to the miR-185 and 5S rDNA promoter, but not a control DNA location. The same ChIP experiments as those described in Figures 2C (exogenous v5-c-Myc in 293 cells) and 2E (endogenous c-Myc in U2OS cells), except the PCR products, were analyzed on an agarose gel. Primers were listed in Table S1.

Figure S3. miR-185-3p affects both of the endogenous and exogenous c-Myc while miR-24 only affects the endogenous c-Myc with 3'UTR. H1299 cells were transfected with indicated plasmids. Twenty hrs after transfection, cells were treated with serum-free medium and stimulated by 20 % FBS, cells were collected 3 hrs after stimulation. Immunoblot (IB) analysis was performed with the N262 anti-c-Myc antibody.

Figure S4. miR-185-3p expression is correlated with c-Myc levels in different human cancer cell lines. Various cancer cells as indicated were harvested at the confluence of ~80% for quantitative real-time PCR (QRT-PCR) and IB assays.

Figure S5. miR-185-3p plays a little role in regulating c-Myc level in response to DNA damage treatment. HCT116 cells were transfected with indicated plasmids and treated with or without 0.3 μM doxorubicin (Dox). IB analysis was performed with the indicated antibodies.

Figure S6. The transactivational activity of exogenous c-Myc is reduced in cultured cells. H1299 cells were infected with ad-c-Myc. Cells were harvested at indicated time points post infection for QRT-PCR assays of the E2F2 mRNA level and for IB analysis of the exogenous c-Myc protein level.


Sample 1
Sample 2
-2.0
0.0
2.0
hsa-miR-140-3p
hsa-miR-145
hsa-miR-584
hsa-miR-23a
hsa-miR-222
hsa-miR-191
hsa-miR-23b
hsa-miR-361-5p
hsa-miR-425
hsa-miR-423-5p
hsa-miR-103
hsa-miR-637
hsa-miR-1469
hsa-miR-193a-5p
hsa-miR-27a
hsa-miR-378
hsa-miR-886-5p
hsa-miR-320a
hsa-miR-320c
hsa-miR-331-3p
hsa-miR-320b
hsa-miR-548h
hsa-miR-107
hsa-miR-18a
hsa-miR-1180
hsa-miR-324-5p
hsa-miR-132
hsa-miR-130b
hsa-miR-210
hsa-miR-20a
hsa-miR-1308
hsa-miR-1975
hsa-miR-24
hsa-miR-498
hsa-miR-548m
hsa-miR-185
hsa-miR-151-3p
hsa-miR-151-5p
hsa-miR-30d
hsa-miR-221
hsa-miR-720
hsa-miR-17
hsa-miR-181a
hsa-miR-93

Fig. S1


A
IP: V5
IP: IgG
input
No DNA
miR-185 promoter
5S rDNA promoter
CT promoter
B
IP: c-Myc
IP: IgG
input
No DNA
miR-185 promoter
5S rDNA promoter
CT promoter

Fig. S2


CT +
pSIF-miR-24 +
pSIF-miR-185-3p +
V5-c-Myc + + +
V5-c-Myc
actin
CT +
pSIF-miR-24 +
pSIF-miR-185-3p +
c-Myc
actin

Fig. S3


140
120
100
80
60
40
20
0
miR-185-3p
RNA Level (fold change)
Jurkat
K562
HCT116
MCF7
U2OS
SAOS2
c-Myc
actin

Fig. S4


HCT116
p53 +/+
miR-185-3p inhibitor +
CT inhibitor +
DMSO +
Dox + +
c-Myc
p53
actin

Fig. S5


RNA Level (fold change)
3
2.5
2
1.5
1
0.5
0
E2F2
Hours after infection
0 h
24 h
48 h
72 h
ad-c-Myc
Hours after infection
0
24
48
72
c-Myc
actin

Fig. S6